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Abstract:
Background:
There is  a  long history of  nuclear  medicine developments  in  orthopaedics  beginning in the early 20th  century.  Technetium-99m
(99mTc) has a short half-life of six hours, emits 140 keV gamma rays and is the most widely used isotope, imaged with the Anger
(gamma) camera. Gamma image quality and test sensitivity in painful prosthetic joints can be improved with single photon emission
computed tomography (SPECT) and SPECT/CT. Positron Emission Tomography-Computed Tomography (PET-CT) with Sodium
Fluoride  (18F-NaF)  and  18Fluorine-fluorodeoxyglucose  (18F-FDG)  PET  have  promising  and  limited  roles  respectively  in  the
investigation  of  painful  prosthetic  joints.  New  SPECT/CT  and  PET-CT  isotopes  targeting  activated  macrophages  with  99mTc
Tilmanocept (Lymphoseek®) and 68Gallium labelled Tilmanocept respectively show potential as agents to demonstrate wear particles
ingested by macrophages and multinucleated giant cells. An imaging algorithm using SPECT and/or PET agents is proffered as a
cost effective way of speedily and accurately arriving a diagnosis.
Methods:
Review of the historical role of nuclear medicine in orthopaedics and research into the potential role of new radiopharmaceutical
agents was undertaken. Guidelines and algorithms for the imaging of complicated joint prosthesis are provided.
Results:
There is an established role for nuclear medicine in orthopaedics and particularly in the investigation of complicated joint prostheses.
Imaging with Tilmanocept provides new opportunities to shorten the time to diagnose loosened and infected joint prostheses.
Conclusion:
There is a potential new role for Tilmanocept, which can be utilised with both PET-CT and SPECT-CT technologies. Tilmanocept is
a relatively new radiopharmaceutical which has a potential role in the imaging assessment of painful joint prosthesis.
Keywords: Joint prosthesis, Septic loosening, Aseptic loosening, Galium-68 Tilmanocept, PET-CT, SPECT-CT.
Nuclear medicine imaging requires molecular probes which are concentrated or altered by specific biological processes
being investigated [1] as well as a means of monitoring these biological probes [1]. Some of the very first attempts in
designing  radionuclides  involved  demonstrating  skeletal  metabolic  change  by  Chiewicz  and  Treadwell  using
Phosphorus-32  and  Strontium-89  respectively  in  the  early  20th  century  [2].
Over time, In vitro alpha, beta  as well  as  gamma emissions  from radioisotopes  in animal  tissue  samples  have been
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demonstrated using autoradiography, Geiger counters and or Sodium Iodide (NaI) crystal detectors [2].
With the use of autoradiography in the musculoskeletal system, isotopes have been incorporated into both the organic
and inorganic components of animal bony skeleton. Cerium as well as Gallium-72 [3] have been deposited in osteoid
tissues and Sulfur-35 labelled Chondroitin Sulfate [2]. Radium D and Thorium B were used to study mineral formation
in bone and teeth [4].
Strontium-85, with a half-life of 65 days and a gamma emission of 514 KeV was the first isotope used in humans in
1956 and between 1956 and 1961 was used to demonstrate increased bone turnover in fractures, tumours, osteomyelitis,
Paget's  disease  and  breast  cancer  bone  metastases  [2].  The  images  were  acquired  2  to  5  days  post-injection  using
external counting with probes [2]. The rectilinear scanner was introduced in the early 1950s to assess thyroid disease
and was later applied to skeletal disease. Image resolution was poor and lumbar and pelvic images took over 2 hours to
acquire [2]. Strontium-87m has a shorter half-life of 2.8 hours and emits 388 keV photons, which is better suited to
scanning than strontium-85 but the high soft tissue activity at the early imaging times, necessitated by its short half-life,
result in inferior images [2].
Fluorine-18 (18F), a cyclotron produced positron emitter with a half-life of 110 minutes [5], is rapidly taken up by bone
and clears  rapidly  from the  soft  tissues,  resulting  in  high  bone:  background ratio  [6]  and the  whole  body could  be
imaged much more quickly with the rectilinear scanner but it had the disadvantage of being more expensive and had a
limited availability [2]. Subsequently, Technetium-99m (99mTc) labelled compounds were employed. Sodium fluoride
Positron Emission Tomography-Computed Tomography (NaF PET-CT) bone imaging is making a resurgence partly
due to the rapid proliferation of clinical PET-CT imaging since 2001 [7 - 9]. Coincident with the introduction of 99mTc
rectilinear photo-scanning systems were replaced gamma-ray scintillation/gamma cameras which were developed by
Hal Anger in the late 1950s [10].
99mTc is more widely available, cheaper and with a gamma emission of 140 keV which is more ideal for gamma camera
imaging. It also has a short half-life of six hours [2]. These features enable higher activity injections in patients with a
low radiation dose, and hence enable swift whole-body imaging [2]. Since 1971, bone scans have been performed with
polyphosphates  and  then  diphosphonates  labelled  with  99mTc  [2].  99mTc  labelled  bone  scans  are  currently  the  most
frequently performed study in nuclear medicine departments in the UK and are likely to be the biggest contributor to
collective radiation dose from diagnostic nuclear medicine studies [11].
Experiments and advancements in translate-rotate motion of scintillation detectors by David Kuhl and Roy Edwards in
the 1960s at the University of Pennsylvania led to the development of computed tomographic imaging, and tomography
reconstruction algorithms which were applied to produce radionuclide single photon emission computed tomography
(SPECT) [2, 12]. SPECT images of the spine and joints have significantly superior sensitivity than planar imaging [2].
Further improvements in test accuracy have come from hybrid fused physiological/anatomical imaging with SPECT/CT
[2]. SPECT/CT provides clarification of the aetiology of indeterminate bone lesions and more correctly classifies bone
tumours than with SPECT alone as well as averting the need to perform supplementary imaging [2].
PET provides cross-sectional images with high-contrast resolution and the ability to quantify levels of radioisotope
uptake  throughout  the  body  [2].  PET  was  initially  described  by  Hal  Anger  in  the  late  1950s  and  is  based  on  the
coincident detection of a pair of annihilated photons that are produced when emitted positron collide with electrons [2].
Positively charged positrons are emitted from the nucleus and have the same mass as electrons [2]. The first fused PET-
CT in-line system with a positron emission tomographic (PET) scanner and a multi–detector row helical computed
tomographic  (CT) scanner  combined as  one machine was introduced in  University  Hospital  Zurich 2001 [13].  Co-
registered PET-CT images showed a significant improvement in lesion classification when compared with PET images
alone  [13].  18Fluorine-fluorodeoxyglucose  (18F-FDG)  PET  is  used  to  image  tumours  as  well  as  inflammatory  and
infectious diseases [2].
18Fluorine sodium fluoride (18F-NaF) is therefore making a return as a bone-imaging agent more than 40 years after its
initial introduction before being surpassed by 99mTc labelled diphosphonates [2]. The rapid proliferation of clinical PET
imaging systems, has revived interest in this agent, which has several advantages over the 99mTc diphosphonates [14,
15]. 18F-NaF does not bind to protein, has a higher capillary permeability and is rapidly cleared from blood resulting in a
higher target-to-background ratio of 18F NaF as well as a twice higher bone uptake [2].
Skeletal  conditions  that  can  be  imaged  accurately  with  99mTc  diphosphonates  and  18F-  NaF  PET  include  fractures,
avascular necrosis, complex regional pain syndrome (CRPS) or reflex sympathetic dystrophy [2] as well as benign bone
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lesions such as fibrous dysplasia, Paget’s disease, osteoid osteoma in addition to bone metastases. It can be difficult to
distinguish  progressive  disease  in  metastatic  bone  disease  from  response  to  treatment  using  99mTc  diphosphonates
because of the flare response in the immediate aftermath of chemotherapy or hormonal treatment and which may last up
to  6  months  [2,  16],  with  this  response  being  more  exaggerated  on  18F NaF PET [16].  18F FDG PET more  closely
reflects  successful  chemotherapy  or  hormonal  treatment  response  in  bone  metastases  and  also  demonstrates  extra-
osseous malignant disease [2, 16]. 18F FDG PET is more sensitive for bone marrow and lytic metastases than sclerotic
deposits [2, 16]. On the other hand, 18F NaF PET and 99mTc -diphosphonates are more sensitive for sclerotic lesions and
lesions with secondary reactive cortical change [2, 16, 17]. Although 18F FDG PET cannot completely obviate the need
for bone biopsies because it cannot consistently distinguish malignant and benign skeletal lesions [2]. 18F FDG PET is
useful for monitoring response to chemotherapy and hormone therapy but a 2 week time delay is required to avoid false
negative results [2].
18F NaF PET-CT has been shown to be more accurate for detecting bone metastases than planar as well as SPECT Tc99m
bone scintigraphy and 18F NaF PET in patients with high-risk prostate cancer [18].
The three-phase bone scan, which analyses bone vascularity, capillary permeability and osteoblastic bone turnover, is a
sensitive  radionuclide  test  for  diagnosing  osteomyelitis,  but  this  remains  a  nonspecific  study [19]  especially  in  the
presence  of  fractures  and  orthopaedic  hardware  which  can  make  image  interpretation  even  more  difficult  [2,  19].
Combined, or sequential nuclear medicine imaging was therefore introduced to improve test specificity [2]: combined
bone/Gallium studies (accuracy of 65%-80%); combined bone/leukocyte studies; combined labelled leukocyte/bone
marrow imaging (accuracy of 90%); as well  as combined bone/sulphur colloid studies [2].  Sulphur colloid marrow
imaging helps map alterations in marrow distribution produced by orthopaedic hardware which may have resulted in
false positive labelled leukocyte studies [2]. Labelled peptides and antigranulocyte antibodies [2].
99mTc-Fanolesomab (NeutroSpec
®
) is a murine M class immunoglobulin that binds to the CD-15 antigen expressed on
human leukocytes with sensitivity comparable to that of in-vitro labelled white cell scans [2], but serious side effects
including  patient  deaths  have  led  to  its  withdrawal  [2].  On  the  other  hand,  Sulesomab  (LeukoScan
®
)  a  murine
monoclonal  (Fab')  antibody  fragment  of  the  lgG  class  is  safer  and  does  not  induce  a  human  anti-mouse  antibody
(HAMA) response [2] following the production of endogenous antibodies. LeukoScan® contains mouse proteins, but
anaphylactic and other hypersensitivity reactions incidents are less common [20].
The Fab' fragment of the IG1 antibody is freely soluble and crosses permeable capillary membranes and then binds to
cross-reactive antigen-90 (NCA-90) on circulating neutrophils at infection sites [2]. Initial result suggested similar or
better results than labelled white cell studies, but more recent studies show less accurate or rather variable results in
diagnosing musculoskeletal infection [2, 20].
FDG-PET  is  less  expensive  for  investigating  bone  infection  than  the  use  of  combination  imaging  with  labelled
leukocyte/bone marrow/bone scans [2] and also hybrid imaging is generally more sensitive than conventional imaging
[21]. However, the presence of prostheses produces mixed results [2] and other metal-ware can result in a reduced test
specificity due partly to false positive results associated with foreign body reactions in aseptically loosened devices
[22]. Initial attempts at human neutrophil imaging in bone infection with 18F FDG PET were initially thought to be
promising [23], but 18F FDG PET has since been shown to be no more sensitive than three-phase bone scintigraphy and
less sensitive than conventional radiography in detecting periprosthetic joint infection [22].
99mTc-labelled Ciprofloxacin (Infecton
®
)  was first  postulated by Solanki [24].  Its  physiological  distribution does not
include the normal bone marrow and this allows for evaluation of the spine and proximal limbs unlike radiolabelled
white cell and Gallium-67 scans which demonstrate background bone marrow uptake [25]. Although initial reports for
the use of 99mTc-labelled Ciprofloxacin in infection were promising [24].  More recent accounts of the use of 99mTc-
labelled Ciprofloxacin show a reduced specificity for detecting of bacterial infections. Also the radioisotope physically
disappeared from sites of infection and inflammation with equal rapidity [26]. Therefore, 99mTc-labelled Ciprofloxacin
has no role of in diagnosing orthopaedic infections [26].
THE DEVELOPMENT OF NEW MOMLECULAR IMAGING PROBES
Radiopharmaceuticals labelled with positron emitting isotopes provide more favourable physical characteristics in
radionuclide imaging than single  photon isotopes  [27].  On the other  hand,  radionuclides  for  single  photon labelled
compounds do provide a wider variety than PET agents and single photon labelled molecules also offer an important
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complimentary array of new possibilities in the development of new agents used in the process of drug development
[27]. Other advantages of PET agents over SPECT agents are the higher sensitivity and more accurate quantification
features [27], but PET agents are disadvantaged by their shorter half-lives and they are also less abundant as well as
more expensive [27]. Single photon emission radionuclides on the other hand are foreign to the human physiology and
biochemistry [28]. Exploratory studies for investigational new drugs (IND) which are also known as phase 0 studies
[29] improve our understanding of toxicity and efficacy thus reducing clinical trial time, costs as well as the high failure
rate of new drugs that occur during the traditional phases I to IV clinical trial stage. Phase 0 studies follow on from
preclinical pharmacology and toxicology tests and occur before the typical Phase I clinical trial. Phase 0 studies may
involve restricted human exposure to non-therapeutic quantities of the IND [29].
Radionuclide  imaging  with  Positron  Emission  Tomography  (PET)  and  Single-Photon  Emission  Computed
Tomography (SPECT) enables speedier proof-of-concept testing and allows non-invasive visualization, characterization
and quantification of biochemical processes that occur at cellular and subcellular levels in both humans and animals
whilst only using nanomolar to picomolar concentrations of the IND [27].
Radionuclide imaging thereforeplays a  big role  in  target  identification and validation.  The drug target  can be a
membrane, nuclear receptor, ion channel, enzyme, hormone, DNA or RNA molecule, or even unidentified biological
entity [27].
Radionuclide imaging does not play a significant role in lead finding and optimization. This stage usually relies on
in  vitro  drug  target  analysis  with  biochemical  and  cellular  assays,  e.g.,  for  compound  purity,  integrity,  solubility,
lipophilicity, safety, dissociation constant, permeability and target affinity [27].
Radionuclide  imaging  is  used  in  compound  profiling  in  animal  models  at  the  preclinical  stage.  In  this,  the
investigative drug itself is labelled with an imaging probe for In vivo imaging using animal models of disease to provide
valuable  information  concerning drug absorption,  distribution,  metabolism,  elimination  and efficacy (ADME).  The
images provide pharmacodynamics and biodistribution properties of a candidate drug [27].
Safety evaluation can involve imaging with animal studies for toxicology and determining the proper dose to be
tested in the clinical trials. Many pharmaceutical companies have established their own imaging laboratories to do carry
out these processes [27].
Clinical  evaluation  with  SPECT  involves  clinical  studies  in  4  sequential  phases  (I–IV)  after  authorization  by
regulatory agencies [27].
REGULATORY BODIES
Worldwide, nuclear Medicine guidelines are developed by a number international, continental, national as well as
local regulatory organisations [30] and the introduction of new isotopes or the institution of new usages of old isotopes
would have to navigate these guidelines and regulations. In Europe, the European Association of Nuclear Medicine
(EANM) coordinates the development of guidelines, but also recognises the need for national guidelines. Likewise, In
the United Kingdom, there are national regulations on the administration of radioactive substances but differences in
clinical practice and service delivery mean that guidelines do not readily apply across regional and national boundaries
[31, 32].
Some examples  of  the  various  statutory  nuclear  medicine  guidelines  and regulatory  bodies  in  England include:
Medicines  and  Healthcare  products  Regulatory  Agency  (MHRA)  which  regulates  the  use  of  new  and  established
medicines and devices; the Carriage of Dangerous Goods and Use of Transportable Pressure Equipment Regulations
2009 regulates the transportation of radioactive substances; the Administration of Radioactive Substances Advisory
Committee (ARSAC); the Radioactive Substances Act 1993 (RSA93) in Scotland, or the Environmental Permitting
Regulations  2010  (EPR2010)  in  England  and  Wales  which  oversees  the  management  of  radioactive  wastes  and  is
policed  by  the  Environment  Agency;  the  Medical  and  Dental  Guidance  Notes  which  covers  Ionising  Radiation
Regulations (IRR99) and is policed by the Health and Safety Executive (HSE). Lastly, there is the Ionising Radiation
(Medical Exposure) Regulations (IRMER) 2000 with inspections carried out by the Care Quality Commission (CQC).
TILMANOCEPT (LYMPHOSEEK®)
The diagnosis of aseptic loosening or infection of joint prosthesis may occur pre-operatively, intra-operatively or
post-operatively  [33].  Periprosthetic  tissue  histological  and  microbiological  features  are  complimentary,  but
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histopathology samples are more reliable than microbiological findings in distinguishing non-infected from infected
revision arthroplasty tissues [34] because organisms are rarely isolated from microbiological cultures of periprosthetic
tissues [34] and almost 11% of cases of false negative microbiological tests occur in septic loosening [34]. Furthermore,
false positive microbiological cultures may also occur due to the growth of contaminants in aseptic loosening [34]. On
the  other  hand,  histology  results  may  be  uninterpretable  due  to  underlying  inflammatory  joint  disease  such  as
rheumatoid  arthritis  [35].
Septic loosening is more reliably diagnosed when acute inflammatory infiltrates are demonstrated using permanent
preparations of periprosthetic tissues with the presence of one or more neutrophil polymorphs per high power field (×
400) on average after the examination of at least 10 high power fields [34, 36]. In addition, histological assessments
may also be carried out intraoperatively on cryostat sections [34].
There are several explanations for the relatively poor microbiological yield. Owing to the low numbers of bacteria
in periprosthetic tissue samples, only a small percentage of samples from infected prostheses would be culture positive
and gram-stains are less  reliable [35].  In addition,  the presence of  comorbidities,  low-virulence organisms,  chronic
infections and infections with fistulae as well as antibiotics or steroids therapy can reduce microbiological yield [37].
Periprosthetic  sampling  sensitivity  can  be  increased  by  using  polymerase  chain  reactions  for  the  detection  of
universal 16S rRNA bacterial genes but this method can also produce false-positive results from necrotic bacteria [38].
However, by combining universal polymerase chain reactions with subsequent bacterial sequencing test specificity can
be improved [38].
During joint revisions, surgical sampling of the prosthetic interface membrane yields better specimens for more
accurate histopathological diagnosis of prosthetic joint infections than from specimens obtained from the pseudocapsule
[39]. In a histopathological study of the periprosthetic membranes performed in 370 patients, 4 types of periprosthetic
membranes have been shown to exist [40]:
Type  I  -  Wear  particle  induced  type  (detection  of  microscopic  foreign  body  particles;  macrophages  and1.
multinucleated giant cells occupy at least 20% of the area [40, 41].
Type II - Infectious type (granulation tissue with neutrophilic granulocytes, plasma cells and few, if any, wear2.
particles [40].
Type III - Combined type (aspects of type I and type II occur simultaneously [40].3.
Type IV - Indeterminate type (neither criteria for type I nor type II are fulfilled [40].4.
In the study, the incidence of histopathological membrane types were: type I  (54.3%), type II  (19.7%), type III
(5.4%) and type IV (15.4%), but 5.1% of cases examined were not assessable [8]. The results showed a high correlation
between histopathological and microbiological results [8].
Periprosthetic interface membrane microscopic particles consist of intra-operative contaminants from surgical tools,
supplemental fixation wires, as well as remnants from surface processing [41]. More commonly, periprosthetic interface
membrane microscopic particles consist of particulate debris created from wear and metal corrosion [41].
There are three main types of wear - adhesion, abrasion and fatigue [41] with the most common particle produced
by wear in the periprosthetic tissues being polyethylene [41], with polymethylmethacrylate (PMMA) another common
wear produced particle [41].
Metal  implant  surface  corrosion  occurs  more  commonly  in  metal-on-metal  modular  interfaces  [41],  producing
particles  which  are  metal-salt  ion  precipitates  produced  in  the  surrounding  aqueous  environment  [41].  Chromium
phosphate particulate debris is produced by corrosion and is the most commonly observed particle in the periprosthetic
tissue specimens retrieved at joint revision [41]. Particulate debris spreads around periprosthetic regions via joint fluid
reaching levels of billion particles per gram of tissue [41]. In addition, Chromium phosphate corrosion particles have
been found at sites remote from joints [41], as well as Cobalt-alloy, and Titanium-alloy particles being other common
corrosion particles produced [41].
Wear  particles  are  under  1µm  in  size,  and  as  such,  cannot  be  visualised  with  light  microscopy  because  the
wavelength of  visible light  ranges from 0.4 to 0.7µm [41].  Because of  this  techniques for  isolation,  separation and
characterisation of wear particles involves the digestion of periprosthetic tissue with proteolytic enzymes and an acid or
alkali [41] making histopathological diagnosis more difficult.
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Periprosthetic wear particles comprise ultra-high molecular weight polyethylene, bone cement, metallic and ceramic
debris  [42].  The  particulate  debris  is  phagocytosed  by  recruited  and  activated  monocytes/macrophages  provoking
chronic inflammation which results in the with resultant bone loss around the prosthesis [42]. The osteolysis following
proliferation, differentiation and activation of macrophages is thought to involve M1 macrophages which promote an
inflammatory response early on following debris formation and subsequently to a lesser degree M2 macrophages which
promote an anti-inflammatory response to promote bone healing, debris scavenging and angiogenesis [42]. This view is
simplistic and even though there is a differential expression of M1 and M2 macrophages in periprosthetic tissues with a
higher ratio of M1/M2 macrophages in debris-laden inflamed periprosthetic and pseudomembrane tissues [42], both M1
and M2 macrophages have both pro- and anti-inflammatory properties [43].
The ideal radiopharmaceutical for joint prosthesis using should be a labelled molecule or simple ion such as 99mTc or
18F labelled for SPECT or PET imaging respectively. These isotopes have relatively short half-lives that allow larger
amounts of radioactivity to be administered without increasing the patients’ absorbed dose [44].
The ideal radiopharmaceutical should be standardized and should require minimal preparation or modification prior
to administration [45]. It should be chemically stable and should preferably injected intravenously in solution form to
avoid  bone  marrow  imaging  [44].  As  with  radiopharmaceuticals  in  general,  it  should  not  elicit  a  pharmaceutical
response or produce any chemical toxicity [44].
Single  photon  imaging  using  Tilmanocept  can  be  performed  with  99mTC  labelled  Tilmanocept  (Lymphoseek®),
which is a radiopharmaceutical comprised of a dextran backbone (10-kilodalton) to which multiple units of mannose
and DTPA (dietylene triamine pentaacetic acid) are attached [46]. The mannose backbone binds to the mannose binding
receptor  CD206 (cluster  of  differentiation)  receptor  with a  sub-nanomolar  affinity  [47]  while  DTPA binds to  99mTc
Lymphoseek
®
 is  licenced for  intradermal,  subcutaneous,  subareolar  and peritumoural  injection routes  for  lymphatic
mapping in the localization of sentinel lymph nodes draining a primary tumours in a variety of cancers. Tilmanocept
travels  easier  in  lymphatic  capillaries  than  blood capillaries  because  lymphatic  capillaries  are  more  permeable  and
larger than blood capillaries, thus enabling easier entry of these relatively large protein particles [48]. Theoretically,
Lymphoseek
®
 binding in  high concentration will  provide evidence of  high numbers  of  macrophages [46,  49].  99mTc
Tilmanocept is FDA approved for use in assessing the nodal spread of squamous cell carcinoma in the head and neck
[50].
There are ongoing trials using intravenous 99mTc Tilmanocept such as in the evaluation of the safety of escalating
doses of 99mTc Tilmanocept by intravenous injection and skeletal joint imaging in patients with rheumatoid arthritis [51].
Another clinical study sponsored by Navidea
®
 Biopharmaceuticals and hosted by Massachusetts General Hospital is
currently  evaluating  arterial  Inflammation  in  patients  infected  with  the  Human  Immunodeficiency  Virus  (HIV)
following  intravenous  injection  of  99mTc  Tilmanocept  [52].  In  the  future,  we  hope  that  after  intravenous  use  of
Tilmanocept has been endorsed for clinical use, it could play a significant role in the evaluation of patients with painful
joint prosthesis as an intravenous macrophage-seeking agent [53].
Intravenous  99mTc  Tilmanocept  has  been  injected  in  animals  [54]  and  has  been  shown  to  localise  in  synovial
macrophages in mice with arthritis [55]. Furthermore, human synovial macrophages have demonstrated Tilmanocept
accumulation In vitro [55].
Tilmanocept  coincidence  imaging  using  PET  may  potentially  be  performed  with  68Gallium  (68Ga)  labelled
Tilmanocept [56, 57]. 68Ga Tilmanocept is produced by chelating radioactive 68Ga to the diethylenetriaminepentaacetic
acid (DTPA) moiety of the Tilmanocept molecule. 68Ga is produced by 68Germanium (68Ge)/68Ga generators that last
serve as a stable source of 68Ga for more than one year [58] and has a half-life of 68 minutes and decays by emitting
positrons  [59].  Experimental  studies  have  combined  Tilmanocept  with  more  widely  available  and  cheaper  18F  to
produce  18F  Tilmanocept  for  PET  imaging  [60].  However,  formation  of  the  C-F  bond  is  a  harsh  laborious  water
sensitive process. Silica-based and boron-based aqueous 18F capture allows direct preparation of 18F Tilmanocept [60].
68Ga Tilmanocept demonstrates a dose-dependent rather low level of bone marrow uptake with peak SUVmax of
approximately 1 to 2. Bone marrow-to-skeletal muscle uptake ratio is approximately 7. Uptake levels in skeletal muscle
is significantly more than liver and lung uptake [47, 61].  68Ga Tilmanocept is  excreted into urine and also binds to
CD206 receptors in mesangial cells within renal glomeruli [62]. A new concept of tri-modal imaging has been created
using 68Ga and 99mTc dual-labelled Tilmanocept combined with a fluorescent near-infrared dye (IRDye800CW) for PET,
SPECT and optical imaging respectively [63]. In vivo Tilmanocept can play an important role in the demonstration of
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CD206 binding intracellular pathogenic organisms such as including bacteria, fungi, viruses and parasites as well as
foreign  materials  [64].  Lymphoseek®  may  perform  as  well  as  histologic  analyses  which  require  an  extended  time
following prosthetic extraction to get an answer.
FOLATE IMAGING
The beta folate receptor (FR-β isoform) is overexpressed on activated macrophages which accumulate at sites of
inflammation and infection. Folate receptor avid isotopes have been shown to accumulate at sites of inflammation and
could  act  as  markers  for  inflammatory  processes  such  as  rheumatoid  arthritis  [65].  In  addition,  to  the  beta  folate
receptor (FR-β isoform), there are 3 other separate types of receptor polypeptides located in cell membranes (α, γ and δ)
which also bind and endocytose folates and folate conjugates. The alpha folate receptor (FR-α isoform) demonstrates
limited expression in normal tissue, mainly kidneys, choroid plexus, lungs, and placenta [66], but is upregulated in
ovarian, uterine, brain, lung, kidney, breast as well as colorectal tumours [65].
PET and SPECT folate imaging can be performed with 18F Fluoro-deoxy-glucose folate PET [66] and 99mTc-EC20
SPECT [66, 67] imaging respectively.
SUMMARY
This paper shows that there is a potential new role for Lymphoseek, which is a relatively new radiopharmaceutical
and that it may be used in the imaging assessment of painful joint prosthesis. The authors also show that Lymphoseek
can be utilised with both PET-CT and SPECT-CT technologies.
It  is  well  recognised  the  nuclear  medicine  studies  have  high  negative  predictive  values  [68]  and  also  that  a
combination of more than one nuclear medicine study would result in a much higher positive predictive value [68]. The
paper also shows that  multimodality imaging which provides complimentary functional  and anatomical  data would
result in improved diagnosis of the state of the periprosthetic membrane [69]. Therefore, a sensible combination of
nuclear medicine studies using SPECT-CT or PET-CT is likely to be highly accurate.
The authors have therefore developed an imaging algorithm (Figs. 1a-e) to reduce false negative and false positive
cases. As discussed, the initial imaging of painful joint prosthesis with 3-phase 99mTc bone SPECT-CT scans or 18F NaF
PET-CT is able to both detect mechanical complications on the CT component as well as cases of infection and aseptic
loosening on the radionuclide component (Figs. 1a-e). The periprosthetic membranes may be assessed further for the
presence of activated macrophages with Tilmanocept or Folate receptor imaging using either SPECT or PET imaging in
patients with no evidence of mechanical complications or infection on their initial imaging. This is especially true in
patients with predominantly late-phase positive isotope bone scans or late phase positive 18F NaF PET [14, 15]. The
presence of a high concentration of macrophages would suggest particulate-induced wear (Type-I) or the combined type
(Type III).
The infectious type (Type II) of periprosthetic membranes which consist of granulation tissue with neutrophilic
granulocytes, plasma cells and few, if any, wear particles are usually obvious on 3-phase 99mTc bone scans SPECT-CT
and 18F NaF PET-CT, but this may be assessed further with labelled white cells or immunoglobulin fragments, using
planar imaging or SPECT if required. Comparative costs of different relevant imaging investigations and their doses is
presented in Table 1.
Table1. Typical cost and radiation dose of commonly performed examinations.
Diagnostic procedure
Typical effective dose
(mSv)
Equivalent number of chest
X-rays
Approx equivalent period of natural
background radiation
Typical Cost
Radiography (Plain Film)
Limbs and joints (except hip) <0.01 <1 <2 days £
Pelvis 0.3 20 1.5 months £
Ultrasound
Ultrasound joint 0 0 0 £
Computed Tomography (CT)
CT pelvis 6 370 2.5 years £ £
Magnetic Resonance Imaging (MRI)
MRI limb 0 0 0 £ £ £
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Diagnostic procedure
Typical effective dose
(mSv)
Equivalent number of chest
X-rays
Approx equivalent period of natural
background radiation
Typical Cost
Radionuclide (Nuclear Medicine)
Bone (Tc-99m-HDP) 3 200 1.3 years £
PET-CT body (NaF or F-18 FDG) 18 1200 8.1 years £ £ £ £
£ - <£35
££ - £35-45
£££ - £45-60££££ - >£60
Some variances: 1 vial of Lymphoseek® costs circa £1,175 (because this is a new patented radiopharmaceutical agent).
A new PET-CT machine with service contract in place will cost approximately £1.6 million.
A modern SPECT-CT gamma camera machine with diagnostic CT capability and service contract in place will cost approximately £ 0.5 million.
Fig. (1a). Dynamic PET-CT initial imaging of painful joint prosthesis – yielding results compatible with normal, aseptic loosening or
infection.
Fig.  (1b).  Dynamic  SPECT-CT  initial  imaging  of  painful  joint  prosthesis  –  yielding  results  compatible  with  normal,  aseptic
loosening or infection (if no PET-CT is available).
(Table ) contd.....
Painful Prosthetic 
joint
infection Aseptic loosening Nomal
Dynamic NaF PET-
CT
 
Painful Prosthetic 
Joint
Infection (3-phase 
uptake)
Aseptic loosening 
(late phase uptake)
Nomal
Dynamic 3-phase 
bone scan with 
SPECT-CT
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Fig.  (1c).  SPECT-CT  labelled  white  cell  imaging  of  suspected  infected  joint  prosthesis  –  yielding  results  compatible  with  no
infection or infection (if no PET-CT is available).
Fig. (1d). SPECT-CT Tilmanocept imaging of suspected aseptic loosening in joint prosthesis – yielding results compatible with a
high macrophage burden or no macrophages (if no PET-CT is available).
Suspected infection 
on 3-phase bone 
scan with SPECT-
CT or NaF PET-CT
infection No infection
Labelled White cell 
scan
SPECT-CT 
Suspected aseptic 
looseing on 3-phase 
bone scan with 
SPECT-CT
Macrophages++ No macrophage
Tilmanocept 99mTc  
SPECT-CT
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Fig. (1e). PET-CT Tilmanocept imaging of suspected aseptic loosening in joint prosthesis – yielding results compatible with a high
macrophage burden or no macrophages.
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